FDA Approves Treatment for Wider Range of Patients with Heart Failure
FDA approves Jardiance (empagliflozin) for wider range of patients with heart failure.
FDA approved Jardiance (empagliflozin) on Feb. 24, 2022 to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.
According to FDA, heart failure affects more than 650,000 people in the United States each year and is the leading cause of hospitalization in people over 65 years of age. Symptoms commonly include shortness of breath, fatigue, and swelling in the legs.
Empagliflozin is meant to reduce the risk of cardiovascular death and hospitalization for patients with heart failure. The drug was originally approved by FDA in 2014 as a diet and exercise supplement to improve glucose control in adults with type 2 diabetes. Empagliflozin is also approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
“Today’s approval will provide a treatment option for a wider range of patients with heart failure,” said Norman Stockbridge, M.D., PhD, director of the Division of Cardiology and Nephrology in FDA’s Center for Drug Evaluation and Research, in a press release. “While Jardiance may not be effective in all patients with heart failure, this approval is a significant step forward for patients and our understanding of heart failure. Coinciding with February’s annual observance of American Heart Month—a reminder for individuals to focus on cardiovascular health—this action will provide physicians another tool to address heart disease.”
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
